Korsuva injection achieves positive topline results in phase III clinical study in Japan for the treatment of pruritus in hemodialysis patients.
Cara Therapeutics, Inc. announced that its licensing partner Maruishi Pharmaceutical Co., Ltd., and its sublicensee Kissei Pharmaceutical Co., Ltd., confirmed the primary endpoint was achieved in a Japanese Phase III clinical study (double-blind, placebo-controlled period) of difelikefalin injection for the treatment of pruritus in hemodialysis patients.